Previously, weve reported information on "one-shot" vaccine, termed as adenovirus vaccine (Ad5-nCoV) (重组新冠病毒疫苗), which came after the better known "two-shot" vaccine that serves as an inactivated vaccine (灭活疫苗). 

 

Most recently, another choice has been available for vaccinators as "three-shot" vaccine is provided in many areas of Guangdong - recombinant subunit vaccine (重组亚单位疫苗). For those applying for an injection, the options are more flexible and diverse.

 

 

Recombinant Subunit Vaccine

With the approval of National Medical Products Administration, the recombinant subunit vaccine (CHO cell) provided now is produced by ZFSW in Anhui Province. It functions similarly with Recombinant Hepatitis B Vaccine (CHO cell) that has been put into use to a large population before in China. Technically, scientists recombine the gene of new coronavirus S protein receptor binding region (RBD) into the hamster ovary (CHO) cell gene. Then expression of RBD dimer is formed in vitro, which is later on added with aluminum hydroxide adjuvant to improve the immunogenicity. People vaccinated with this kind of vaccine will have neutralizing antibodies so as to achieve the purpose of preventing infection with COVID-19.

 

Vaccinator

Currently people aged at 18 and above can be vaccinated.

 

Vaccination Process

3 doses required with a recommended interval of 4+ weeks between each; the second dose is recommended to be completed within 8 weeks after the first one; the third dose should be completed within 6 months after the first dose.

 

Effect

The vaccine has been proven effective in protection against the virus based on data. As shown in a two-phase clinical research among adults with an age range from 18 to 59, positive conversion rate of neutralizing antibodies in Euvirus had reached 83% after the two doses had been vaccinated, and positive conversion rate of neutralizing antibodies in Euvirus had reached 97% after the third dose had been vaccinated, as evidenced by serum neutralizing antibody level twice as much as that of patients who recovered from COVID-19, as well as a 99% positive conversion rate in RBD protein-binding antibody.

 

Safety

Based on safety monitoring data collected by Chinese Center for Disease Control and Prevention (CDC) on May 28th, the normal reaction and abnormal reaction rate of COVID-19 vaccine are lower than the average reported level of other types of vaccines in 2019.

 

Author | Jersey

Source | 广东疾控, Foshan News Network

Photo | 广东省预防医学会